Cipla receives EUA for oral antiviral drug to treat mild to moderate Covid
Cipla plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate Covid-19 at high risk of developing severe disease
Drug major Cipla on Tuesday said it has received emergency use authorisation (EUA) permission from the Drug Controller General of India (DCGI) to launch antiviral drug Molnupiravir in the country to treat mild-to-moderate COVID19. The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu, Cipla receives EUA for oral antiviral drug to treat mild to Pharma oral antiviral drug Medical research EUA Covid-19 Cipla "This launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients," Cipla MD and Global CEO Umang Vohra said in a statement. Earlier during the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs). The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-tomoderate COVID-19 at high risk of developing severe disease. Molnupiravir inhibits the replication of multiple RNA viruses including SARS-CoV2. Cipla said it will soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID treatment centers across the country. The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!